| abstract |
FIELD: pharmacology. n SUBSTANCE: group of inventions is a Ras antagonist represented by the formula R 1 -R 2 -R 3 -R 4 , where: R 3 is S; R 4 is farnesyl or geranyl-geranyl, wherein geranyl-geranyl has the structure n : n R 2 is a 5-membered heterocyclic ring containing one S heteroatom; R 1 is C(=O)R 5 , CO 2 M; R 5 is hydroxyl; M is a salt forming an organic or inorganic counterion; and R 8 is hydrogen or C1-C4 alkyl; and pharmaceutically acceptable salts thereof; or R 1 is a 5-membered heterocyclic ring containing 2-4 N heteroatoms and R 2 is a phenyl ring; or R 2 is a 5-membered heterocyclic ring containing three heteroatoms selected from N and S, and R 1 is C(=O)R 10 , and R 10 is hydrogen, hydroxyl or C1-C4 alkyloxy. The invention also relates to a method for inhibition of Ras-induced cell proliferation associated with a malignant or non-malignant disease, comprising Ras antagonist administration to a patient. n EFFECT: increased efficiency of treatment. n 20 cl, 9 ex, 7 dwg |